Evidence map›Paper›PMID 25496873›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2015

Carriers of a common variant in the dopamine transporter gene have greater dementia risk, cognitive decline, and faster ventricular expansion.

Florence F Roussotte, Boris A Gutman, Derrek P Hibar, Sarah K Madsen, Katherine L Narr, Paul M Thompson, Alzheimer's Disease Neuroimaging Initiative (ADNI)

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Parkinson disease-associated cognitive impairment.Nature reviews. Disease primers · 2021
    Review
  9. Article
  10. Review
  11. Common Variants inFrontiers in neuroscience · 2018
    Article
  12. Review
  13. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Florence F RoussotteDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Imaging Genetics Center, Institute for Neuroimaging and Informatics, Department of Neurology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA, USA.
Boris A GutmanImaging Genetics Center, Institute for Neuroimaging and Informatics, Department of Neurology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA, USA.
Derrek P HibarImaging Genetics Center, Institute for Neuroimaging and Informatics, Department of Neurology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA, USA.
Sarah K MadsenImaging Genetics Center, Institute for Neuroimaging and Informatics, Department of Neurology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA, USA.
Katherine L NarrDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Paul M ThompsonDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Imaging Genetics Center, Institute for Neuroimaging and Informatics, Department of Neurology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Departments of Psychiatry, Engineering, Radiology, & Ophthalmology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: pthomp@usc.edu.
Alzheimer's Disease Neuroimaging Initiative (ADNI)
University of Southern California · USAlzheimer’s Disease Neuroimaging Initiative · USUniversity of California, Los Angeles · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI DECARLI, CHARLES · 1991 to 2020
$28.3M
Training U54EB020403 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2014 to 2018
$10.1M
Growth factors, neuroinflammation, exercise, and brain integrityRF1AG041915 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2014 to 2014
$2.9M
Alzheimer's disease risk analyzed using population imaging genomicsR01AG040060 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2011 to 2016
$2.5M
Empowering Personalized Medicine: Integrating Imaging, Genetics, and BiomarkersR01MH097268 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COPPOLA, GIOVANNI, THOMPSON, PAUL M · 2012 to 2014
$1.3M
Biomarkers of fast acting therapies in major depressionK24MH102743 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NARR, KATHERINE L · 2014 to 2018
$889k
"MR Morphometrics and Cognitive Decline Rate in Large-Scale Aging Studies"K01AG030514 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARMICHAEL, OWEN T. · 2008 to 2012
$495k
NIA NIH HHS K01 AG030514NIA NIH HHS P30 AG010129NIA NIH HHS R01 AG040060NIA NIH HHS RF1 AG041915NIA NIH HHS U01 AG024904NIBIB NIH HHS U54 EB020403NIMH NIH HHS K24 MH102743NIMH NIH HHS R01 MH097268
6 · The paper itself

Abstract

introductionGenetic variants in DAT1, the gene encoding the dopamine transporter (DAT) protein, have been implicated in many brain disorders. In a recent case-control study of Alzheimer's disease (AD), a regulatory polymorphism in DAT1 showed a significant association with the clinical stages of dementia.

methodsWe tested whether this variant was associated with increased AD risk, and with measures of cognitive decline and longitudinal ventricular expansion, in a large sample of elderly participants with genetic, neurocognitive, and neuroimaging data from the Alzheimer's Disease Neuroimaging Initiative.

resultsThe minor allele-previously linked with increased DAT expression in vitro-was more common in AD patients than in both individuals with mild cognitive impairment and healthy elderly controls. The same allele was also associated with poorer cognitive performance and faster ventricular expansion, independently of diagnosis. DISCUSSION: These results may be due to reduced dopaminergic transmission in carriers of the DAT1 mutation.

Indexed as

AgedAged, 80 and overAllelesAlzheimer DiseaseCase-Control StudiesCerebral VentriclesCognitionCognitive DysfunctionDopamine Plasma Membrane Transport ProteinsFemaleGenotypeHeterozygoteHumansMagnetic Resonance ImagingMalePolymorphism, GeneticDopamine Plasma Membrane Transport ProteinsSLC6A3 protein, humanDAT1DementiaDopamine transporterNeuroimaging geneticsVentricular expansion

Identifiers

PMID25496873
PMCPMC4465053
OpenAlexW2033188976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.